Across TCGA pan-cancer cohorts, RNY3P2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNY3P2 data layer.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNY3P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNY3P2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
HNSC, READ, and KIRP are the cancer types where RNY3P2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.